Contiguous Verrucous Proliferations in Syringocystadenoma Papilliferum: A Retrospective Analysis With Additional Evaluation via Mutation-Specific BRAF V600E Immunohistochemistry

Document Type

Conference Proceeding

Publication Date

5-1-2018

Publication Title

Am J Dermatopathol

Abstract

There have been several reports describing collision lesions of syringocystadenoma papilliferum (SCAP) and verruca, although little is known about the frequency of this association. Molecular testing has revealed the BRAFV600E mutation in a large proportion SCAP cases, although its expression pattern has not been previously evaluated. In a retrospective analysis, we explored the potential histopathological association between verruca and SCAP. We also evaluated mutation-specific BRAF V600E expression in these lesions by immunohistochemistry. Cases of SCAP diagnosed over a 7-year period were closely reviewed for the presence of contiguous verrucous proliferations. Additional sections were cut and stained using the BRAF V600E specific clone VE1 antibody. Contiguous verrucous proliferations were identified in 9 out of 12 identified cases. Expression of the BRAF V600E mutation was identified in 7 out of 12 cases. Interestingly, in SCAP associated with endophytic verrucous proliferations, expression of BRAF V600E was found in both the glandular and the contiguous hyperplastic squamous epithelium. Overall, these findings suggest that contiguous verrucous proliferations in SCAP are common. Both components of the neoplasm may express the BRAFV600E mutation, which implicates a common origin.

Volume

40

Issue

5

First Page

e67

Find It @ Sladen

Share

COinS